NUVATION BIO INC (NUVB:NYSE)
$5.12 -0.02 (-0.3891%)
Analysed NUVATION BIO INC (NUVB:NYSE) News Sources
Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying.
15-05-2026
yahoo.com
Kestra Medical Grew Revenue 63%. One Fund Still Trimmed 351,000 Shares
15-05-2026
fool.com
Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back
15-05-2026
fool.com
Bicara Stock Is Up 50%, and One Biotech Investor Has Made It a 29% Portfolio Bet
15-05-2026
fool.com
Thermo Fisher Deepens Oncology Role With Ibtrozi Manufacturing Milestone
18-05-2026
yahoo.com
Nuvation Bio Sharpens IBTROZI Focus With Thermo Fisher And FDA Steps
18-05-2026
yahoo.com
Nuvation Bio to Present New Quality-of-Life Data for IBTROZI® (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2026 Annual Meeting
27-05-2026
yahoo.com
Nuvation Bio to Present at the Jefferies Global Healthcare Conference
27-05-2026
yahoo.com
Spotlight On Promising Penny Stocks For June 2026
10-06-2026
yahoo.com
Here’s What the Acquisition of Nuvalent Means for Nuvation Bio (NUVB)
16-06-2026
yahoo.com
What is the current price of NUVATION BIO INC (NUVB:NYSE)?
The current price of NUVATION BIO INC (NUVB:NYSE) is $5.12.
NUVATION BIO INC (NUVB:NYSE) absolute price change since previous trading day?
The absolute price change of NUVATION BIO INC (NUVB:NYSE) since the previous trading day is $-0.02.
NUVATION BIO INC (NUVB:NYSE) percentage price change since previous trading day?
The percentage price change of NUVATION BIO INC (NUVB:NYSE) since the previous trading day is -0.3891%.
What is the most recent average sentiment score for NUVATION BIO INC (NUVB:NYSE)?
The most recent average sentiment score for NUVATION BIO INC (NUVB:NYSE) is 86 out of 100.
What is the most recent average sentiment for NUVATION BIO INC (NUVB:NYSE)?
The most recent sentiment for NUVATION BIO INC (NUVB:NYSE) is .
SEC-8K** Filing Available For NUVATION BIO INC (NUVB:NYSE)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.